Eliminating bacteria backbone of naked DNA enhanced hFIX expression and reduced inflammatory response in mice

Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie
Huan-Zhang ZhuW Jia

Abstract

To test the hypothesis that the persistent high level of transgene expression of linear DNA eliminating bacterial backbone (LDEBB) results from less cytokine induction in vivo. We systematically investigated the effect of circular DNA (C DNA), linear DNA (L DNA) and LDEBB on gene expression in mice by hydrodynamics-based plasmid administration, and then determined serum cytokine levels in mice by enzyme linked immunosorbent assay (ELISA). The expression of human clotting factor IX (hFIX) gene in mice treated with LDEBB, L DNA or C DNA reached a maximum 1-day after injection (9809, 6447, 2368 ng/mL), respectively. Thirty days after injection, hFIX concentrations dropped to baseline in mice treated with C DNA group, while L DNA group and LDEBB group decreased to 207 and 377 ng/mL, respectively, at the same time-point. Mice receiving LDEBB encoding hFIX expressed approximately 1.5 to 20-fold more serum hFIX than mice injected with L DNA and C DNA for a period of 8 months, respectively. However, mice receiving LDEBB are much less inflammatory than L DNA and C DNA as shown by a 4-fold reduction in serum levels of both TNF-alpha and IL-12. These results demonstrate that LDEBB is not silenced and is capable of expressing persistently ...Continue Reading

References

Sep 1, 1992·Human Molecular Genetics·J A WolffA Jani
Apr 6, 1995·Nature·A M KriegD M Klinman
Jan 6, 1999·Proceedings of the National Academy of Sciences of the United States of America·M A ZantaJ P Behr
Sep 25, 1999·Human Gene Therapy·F Paillard
Mar 29, 2001·Molecular Therapy : the Journal of the American Society of Gene Therapy·Z Y ChenM A Kay
Apr 3, 2001·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·J YangY Liu
Jul 27, 2001·Molecular Therapy : the Journal of the American Society of Gene Therapy·N S YewS H Cheng
Nov 20, 2001·The Journal of Biological Chemistry·Xiaowu LiangPhilip L Felgner
Apr 20, 2002·Science·Zhixiong LiChristopher Baum
Aug 31, 2002·Cell·Astrid R W SchröderFrederic Bushman
Jan 17, 2003·The New England Journal of Medicine·Salima Hacein-Bey-AbinaAlain Fischer
May 3, 2003·Nature Reviews. Genetics·Clare E ThomasMark A Kay
Aug 30, 2003·Molecular Therapy : the Journal of the American Society of Gene Therapy·Zhi-Ying ChenMark A Kay
Mar 12, 2005·Nature Reviews. Genetics·Dominic J GloverDavid A Jans

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.